8158 Stock Overview
An investment holding company, engages in the provision of healthcare products and services in Hong Kong and the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
China Regenerative Medicine International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.35 |
| 52 Week High | HK$1.27 |
| 52 Week Low | HK$0.094 |
| Beta | 0.96 |
| 1 Month Change | 11.11% |
| 3 Month Change | 250.00% |
| 1 Year Change | -45.31% |
| 3 Year Change | -87.72% |
| 5 Year Change | -83.17% |
| Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding
Mar 05
China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%
Jan 04These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet
Jun 11Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year
Mar 16What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?
Feb 08Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares
Dec 15
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)
Nov 25Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24Shareholder Returns
| 8158 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -23.9% | -3.9% | -0.5% |
| 1Y | -45.3% | -5.7% | 19.9% |
Return vs Industry: 8158 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 8158 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 8158 volatility | |
|---|---|
| 8158 Average Weekly Movement | 93.6% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 8158's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8158's weekly volatility has increased from 49% to 94% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 39 | Chuang Wang | www.crmi.hk |
China Regenerative Medicine International Limited, an investment holding company, engages in the provision of healthcare products and services in Hong Kong and the People’s Republic of China. It operates through Aesthetic Medical and Beauty Services; and Medical Services segments. The company offers medical beauty products and services; and medical products and services.
China Regenerative Medicine International Limited Fundamentals Summary
| 8158 fundamental statistics | |
|---|---|
| Market cap | HK$106.49m |
| Earnings (TTM) | -HK$103.63m |
| Revenue (TTM) | HK$55.06m |
1.9x
P/S Ratio-1.0x
P/E RatioIs 8158 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8158 income statement (TTM) | |
|---|---|
| Revenue | HK$55.06m |
| Cost of Revenue | HK$26.63m |
| Gross Profit | HK$28.43m |
| Other Expenses | HK$132.06m |
| Earnings | -HK$103.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 51.63% |
| Net Profit Margin | -188.23% |
| Debt/Equity Ratio | 164.0% |
How did 8158 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 23:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Regenerative Medicine International Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|